Tryp Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRYP.CN research report →
Companywww.tryptherapeutics.com
Tryp Therapeutics Inc. , a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin.
- CEO
- Jason Carroll
- IPO
- 2020
- HQ
- Kelowna, BC, CA
Price Chart
Valuation
- Market Cap
- $5.79M
- P/E
- -1.10
- P/S
- 0.00
- P/B
- -1.54
- EV/EBITDA
- -1.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 402.50%
- ROIC
- 356.62%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-5,267,073 · 29.73%
- EPS
- $-0.05 · 44.06%
- Op Income
- $-4,701,745
- FCF YoY
- 38.96%
Performance & Tape
- 52W High
- $0.06
- 52W Low
- $0.06
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -1.28
- Avg Volume
- 0
Get TickerSpark's AI analysis on TRYP.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TRYP.CN Coverage
We haven't published any research on TRYP.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TRYP.CN Report →